At a glance
- Originator Roche
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 24 Jul 1995 Discontinued-I for Hyperlipidaemia in Switzerland (Unknown route)
- 12 Jul 1995 New profile